On the other hand, two other pre-clinical studies using a CT26 xenograft model showed improved local tumor control, long-term survival, and protection against tumor re-challenge when 5 × 2 Gy RT was combined with anti-PD1 or anti-PD-L1 antibodies [164,190]. This evidence concerns the gene CD274 and neoplasm.